The cost of Exparel in 2019 varied depending on factors such as insurance coverage, the specific healthcare setting, and the volume purchased by providers. While an exact average cost is not readily available, the drug was typically administered by healthcare professionals, and its price reflected its use as a long-acting local anesthetic intended to provide post-operative pain relief for extended periods.
How much did Exparel cost per dose in 2019?
Specific pricing for Exparel per dose in 2019 was not publicly disclosed as a fixed retail price. Instead, the cost to hospitals and surgical centers would have been influenced by negotiated contracts and formulary status. Patients' out-of-pocket expenses would have been determined by their insurance plans, including deductibles, co-pays, and co-insurance. For individuals without insurance, the cost could have been considerably higher.
What factors influence Exparel's price?
Exparel's price is influenced by several elements. These include the manufacturing costs associated with its unique liposomal encapsulation technology, which allows for sustained release of the active ingredient, bupivacaine [1]. Research and development investments, clinical trial expenses, and regulatory approval processes also contribute to the drug's overall cost. Furthermore, market demand and competition play a role in pricing strategies.
When did Exparel's patents expire?
The patent landscape for Exparel is complex, with multiple patents covering its composition, manufacturing, and methods of use. While the initial patents may have had varying expiry dates, information from DrugPatentWatch.com indicates that key patents protecting Exparel had expiration dates extending into the late 2020s and beyond for some formulations or indications [2]. This extended patent protection would have generally limited the market entry of generic alternatives in 2019.
Can generic Exparel be available before patent expiry?
Generally, generic versions of a drug cannot be marketed until the relevant patents expire or are successfully challenged. In 2019, the patent protection for Exparel meant that generic alternatives were not widely available. Any potential for earlier market entry would typically involve legal challenges to existing patents or the development of new formulations or indications that do not infringe upon existing intellectual property.
What is Exparel used for and how does it work?
Exparel is a non-opioid analgesic used to control post-operative pain. It is a liposomal formulation of bupivacaine, a local anesthetic. The liposomal technology encases the bupivacaine, allowing for a slow and sustained release of the drug into the local tissue over a period of up to 72 hours after a single administration. This extended release mechanism aims to reduce the need for opioid pain medications and their associated side effects [1].
How does Exparel's cost compare to other pain management options?
When considering the cost of Exparel, it is often compared to the cumulative cost of alternative pain management strategies over the post-operative period. These alternatives might include the cost of multiple doses of shorter-acting local anesthetics, opioid medications, and the associated healthcare resources and potential management of side effects. While Exparel has a higher upfront cost per administration, its ability to provide prolonged pain relief could potentially lead to cost savings by reducing the need for other interventions and shorter hospital stays in some cases.
Sources:
[1] Pacira BioSciences, Inc. EXPAREL® (bupivacaine). https://www.exparel.com/
[2] DrugPatentWatch.com